Amneal Pharmaceuticals Inc., trading as AMRX, has announced that it's received an Abbreviated New Drug Application approval from the U.S. Food and Drug Administration. This approval is for an otic suspension of ciprofloxacin and dexamethasone.
This product combines ciprofloxacin, a type of fluoroquinolone antibacterial, with dexamethasone, a corticosteroid. It is designed for treating infections caused by exposure to certain microorganisms. It's specifically used for treating Acute Otitis Externa (AOE), which is an ear condition affecting people from the age of six months upwards, including adults and senior citizens. The infections this treatment targets are typically caused by staphylococcus aureus and pseudomonas aeruginosa.
There have been reports of some adverse reactions associated with the ciprofloxacin and dexamethasone otic suspension, including ear pain (2.3% of cases), discomfort in the ear (3%), and itching in the ear (1.5%).
For more health news, go to rttnews.com.
